- Home
- HSIC vs EXEL Comparison
HSIC vs EXEL Comparison
Compare HSIC & EXEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HSIC
- EXEL
- Stock Information
- Founded
- HSIC 1932
- EXEL 1994
- Country
- HSIC United States
- EXEL United States
- Employees
- HSIC N/A
- EXEL N/A
- Industry
- HSIC Medical Specialities
- EXEL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- HSIC Health Care
- EXEL Health Care
- Exchange
- HSIC Nasdaq
- EXEL Nasdaq
- Market Cap
- HSIC 8.9B
- EXEL 9.7B
- IPO Year
- HSIC 1995
- EXEL 2000
- Fundamental
- Price
- HSIC $68.58
- EXEL $34.45
- Analyst Decision
- HSIC Buy
- EXEL Buy
- Analyst Count
- HSIC 10
- EXEL 18
- Target Price
- HSIC $77.50
- EXEL $31.72
- AVG Volume (30 Days)
- HSIC 1.6M
- EXEL 2.6M
- Earning Date
- HSIC 11-05-2024
- EXEL 10-29-2024
- Dividend Yield
- HSIC N/A
- EXEL N/A
- EPS Growth
- HSIC N/A
- EXEL 441.02
- EPS
- HSIC 2.42
- EXEL 1.55
- Revenue
- HSIC $12,499,000,000.00
- EXEL $2,081,598,000.00
- Revenue This Year
- HSIC $6.26
- EXEL $20.53
- Revenue Next Year
- HSIC $3.85
- EXEL $1.54
- P/E Ratio
- HSIC $28.36
- EXEL $22.26
- Revenue Growth
- HSIC N/A
- EXEL 17.31
- 52 Week Low
- HSIC $63.67
- EXEL $19.20
- 52 Week High
- HSIC $82.63
- EXEL $36.60
- Technical
- Relative Strength Index (RSI)
- HSIC 35.61
- EXEL 67.10
- Support Level
- HSIC $67.91
- EXEL $27.86
- Resistance Level
- HSIC $71.35
- EXEL $36.49
- Average True Range (ATR)
- HSIC 1.56
- EXEL 0.98
- MACD
- HSIC -0.43
- EXEL -0.01
- Stochastic Oscillator
- HSIC 0.00
- EXEL 74.10
About HSIC Henry Schein Inc.
Henry Schein Inc is a solutions company for healthcare professionals powered by a network of people and technology. The company is a provider of healthcare products and services primarily to office-based dental and medical practitioners, as well as alternate sites of care. The company operates in two reportable segments; health care distribution and technology & value-added services. The healthcare distribution segment is engaged in combining global dental and medical businesses and distributes consumable products, small equipment, laboratory products, and Vitamins. The technology and value-added services reportable segment provides software, technology & other value-added services to health care practitioners. The majority of revenue is derived from the health care distribution segment.
About EXEL Exelixis Inc.
Exelixis is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its lead molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.